Save
How to Plan Follow Up in the Light of Treatment of Oligometastatic Disease?
ESGO eAcademy, Maja Pakiz, 403825
The Effects Of Niraparib Dose Reduction On Long-Term Outcomes In Ovarian Cancer Patients: A Large Retrospective, Observational Study
ESGO eAcademy, ADRIANA IONELIA APOSTOL, 403832
Role of Lymphadenectomy (LND) in Advanced Ovarian Cancer (OC) – A Subgroup Analysis of the Patients Excluded from the Original Lion Trial (The Charité Cohort)
ESGO eAcademy, Robert Armbrust, 403831
PARP Inhibitors
ESGO eAcademy, Thomas A. McKee, 403827
Role and Challenges of Radiation Treatment for Oligometastatic Disease
ESGO eAcademy, Sturdza Alina Emiliana, 403824
Global Variations In The Management Of Low-Grade Serous Carcinoma Of The Ovary.
ESGO eAcademy, BISWAJIT DASH, 403830
Observer-Reality Agreement In Assessing Ovarian Cancer Spread And Predicting Non-Resectability In Ovarian Cancer (ISAAC Study, Imaging Study On Advanced Ovarian Cancer)
ESGO eAcademy, Umberto Scovazzi, 403829
Endocrine Therapy
ESGO eAcademy, Viola Heinzelmann-Schwarz, 403826
Role and Challenges of Surgical Treatment for Oligometastatic Disease
ESGO eAcademy, Giovanni Scambia, 403823
Management of VAIN
ESGO eAcademy, Vesna I. Kesic, 403822
Clinical Evidence in Endometrial Cancer
ESGO eAcademy, Mansoor Raza Mirza, 403819
Is HIPEC a Standard or an Option in Ovarian Cancer? CON
ESGO eAcademy, Ignace Vergote, 403816
Management of VIN
ESGO eAcademy, Mario Preti, 403821
Biological Rationale of Immunotherapy (Single Agent and in Combination)
ESGO eAcademy, Robert L. Coleman, 403818
Management of CIN and Role of Vaccination after Treatment
ESGO eAcademy, Maria Kyrgiou, 403820
From Historical Classification to Molecular Classification
ESGO eAcademy, Xavier Matias-Guiu, 403817
Is HIPEC a Standard or an Option in Ovarian Cancer? PRO
ESGO eAcademy, Giovanni Scambia, 403815
MENA Region (Middle East and North Africa): Experience Bridging the Gaps in the Gynaecological Oncology World
ESGO eAcademy, Basel Refky, 403814
Advances in Radiotherapy for Recurrent Cervical Cancer
ESGO eAcademy, Alexandra Taylor, 403806
Surgical Staging Revisions in Advanced Stage Endometrial Cancer
ESGO eAcademy, Christina Fotopoulou, 403810
How Well Prepared is Latin America for Implementing 90-70-90 WHO Strategy
ESGO eAcademy, René Pareja, 403813
Recurrent/Metastatic Cervical Cancer Not Amenable for Curative Treatment
ESGO eAcademy, Ana Oaknin, 403805
Molecular Classification Goes FIGO
ESGO eAcademy, Nicole Concin, 403809
Barriers and Opportunities for Global Collaborative Research
ESGO eAcademy, Jalid Sehouli, 403812
Pelvic Exenteration in Patients with Persistent and Recurrent Cervical Cancer: An Experience at National Cancer Centre of Belarus
ESGO eAcademy, Olga P Matylevich, 403804
Key New Histopathological Aspects
ESGO eAcademy, Xavier Matias-Guiu, 403808
Introduction: Opportunities and Challenges in the Development of the Updated FIGO Classification
ESGO eAcademy, Nicole Concin, 403807
ESGO/ESTRO/ESP Cervical Cancer Guidelines Adopted for Low-Income Countries
ESGO eAcademy, David Cibula, 403811
Session Opening, Voting
ESGO eAcademy, Ana Oaknin, 403803
Landmark Successes in Our Journey Towards Optimised Treatment
ESGO eAcademy, Ozden Altundag, 403790
Navigating the Path to Personalised First-Line Therapy
ESGO eAcademy, Christian Marth, 403791
General Q&A and Close
ESGO eAcademy, Ozden Altundag, 403793
Discussant
ESGO eAcademy, Coleman Robert, 403784
Laparoskopic Infralevatoral Total Pelvic Exenteration
ESGO eAcademy, Mustafa Deveci, 403789
Efficacy Of Subsequent Chemotherapy Followed By PARP Inhibitor Maintenance In Patients With Advanced Ovarian Cancer In The Phase III PAOLA-1/ENGOT-Ov25 Trial
ESGO eAcademy, Christian Marth, 403783
Video-Endoscopic Inguinal Sentinel Lymph Node Biopsy With Indocyanine Green In Vulvar Cancer
ESGO eAcademy, Bizzarri Nicolo, 403788
Uterine Preservation (with BSO) in FSS of Ovarian Cancers and the Need for Completion Surgery in EOCs and SCTs
ESGO eAcademy, Alexandros Rodolakis, 403778
Final Overall Survival And Long-Term Safety In The ENGOT-OV16/NOVA Phase 3 Trial Of Niraparib In Patients With Recurrent Ovarian Cancer
ESGO eAcademy, Mansoor Raza Mirza, 403782
Discussant
ESGO eAcademy, Isabelle Ray-Coquard, 403781
Management of Fertility after FSS in Epithelial Cancers and SCTs
ESGO eAcademy, Michael Grynberg, 403777
Initial Efficacy And Safety Results From ENGOT-Ov60/GOG-3052/RAMP 201: A Phase 2 Study Of Avutometinib (VS-6766) ± Defactinib In Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
ESGO eAcademy, Banerjee Susana, 403780
ICON8B: GCIG Phase III Randomised Trial Comparing Weekly Dose-Dense Chemotherapy + Bevacizumab To Three-Weekly Chemotherapy+ Bevacizumab In First-Line High-Risk Stage III-IV Epithelial Ovarian Cancer Treatment: Primary Progression-Free Survival Analysis
ESGO eAcademy, Andrew Clamp, 403779
FSS Options in Early and Advanced Stages LGSCs
ESGO eAcademy, Nadeem R. Abu-Rustum, 403776
Total Laparoscopic Radical Parametrectomy With Pelvic Lymphadenectomy
ESGO eAcademy, Amal AlSomairi, 403785
Application Of Endometrial Cancer Molecular Classification To Endometriosis-Related Ovarian Cancer: A Single Center Preliminary Data
ESGO eAcademy, Serena Cappuccio, 403775
PRO Drains: Is There Ever an Indication?
ESGO eAcademy, Erick Estrada, 403764
CON Drains: Is There Ever an Indication?
ESGO eAcademy, Irina Tsibulak, 403765
Has Time To Chemotherapy From Primary Debulking Surgery In Advanced Ovarian Cancer An Impact On Survival? - A Population-Based Nationwide SweGCG Study
ESGO eAcademy, Pernilla Dahm Kähler, 403774
PRO Minimally Invasive Surgery: Outpatient or Inpatient
ESGO eAcademy, Erick Estrada, 403762
CON Minimally Invasive Surgery: Outpatient or Inpatient
ESGO eAcademy, Irina Tsibulak, 403763
Evolutionary Study Identifies Poor Prognosis HGSC Patients And Reveals Clinically Relevant Targets At Diagnosis And Relapse
ESGO eAcademy, Jaana Oikkonen, 403773
Manifesto of Young Gyn Oncologists for Cervical Cancer Elimination
ESGO eAcademy, Joanna Kacperczyk-Bartnik, 403768
PRO Bowel Preparation: All, Some, or None
ESGO eAcademy, Irina Tsibulak, 403760
CON Bowel Preparation: All, Some, or None
ESGO eAcademy, Erick Estrada, 403761
The Correlation Between Macroscopic Surgical Assessment, Histological And Molecular Subtypes Of High-Grade Serous Cancer Of The Female Genital Tract, Ovarian, Tubal And Peritoneal Origin- The FOoTPrint Study
ESGO eAcademy, yael Naaman, 403771
video for re-upload
ESGO eAcademy, Faculty / Presenter(s), 405208
Update in HPV Screening Globally
ESGO eAcademy, Marc Arbyn, 403767
CON Carbohydrate Loading: Evidence of Hype
ESGO eAcademy, Erick Estrada, 403759
PRO Carbohydrate Loading: Evidence of Hype
ESGO eAcademy, Irina Tsibulak, 403758
Implementation Of Scottish National Ovarian Cancer Quality Performance Indicators – The Process And The Outcomes.
ESGO eAcademy, Aiste McCormick, 403770
PRO Prehabilitation: Feasibility and Outcomes
ESGO eAcademy, Erick Estrada, 403757
CON Prehabilitation: Feasibility and Outcomes
ESGO eAcademy, Irina Tsibulak, 403756
Homologous Recombination Deficiency (HRD) Testing On Cell-Free Tumor DNA From Peritoneal Fluid Of Patient With Epithelial Ovarian Cancer
ESGO eAcademy, Alexandra Leary, 403769
Current State of the Art in HPV Vaccines
ESGO eAcademy, Murat Gultekin, 403766
Possibilities of Fertility Preservation for Uterine Stromal Tumours
ESGO eAcademy, Ignacio Zapardiel, 403754
Hepatic and Gastric Cytoreductive Techniques
ESGO eAcademy, Santiago Domingo, 403750
Case Presentation 2 + Discussion
ESGO eAcademy, Pawel Knapp, 403753
Distal Pancreatectomy, Splenectomy and Radical Omentectomy
ESGO eAcademy, Glauco Baiocchi, 403749
Case Presentation 1 + Discussion
ESGO eAcademy, Se Ik Kim, 403752
Introduction
ESGO eAcademy, Ignacio Zapardiel, 403751
Diaphragmatic and Pleural Cytoreduction, Paracardiac Lymph Node Resection
ESGO eAcademy, Christina Fotopoulou, 403748
Should All HRD/BRCA WT Patients Be Treated With PARP+ Antiangiogenic Agents? CON Opinion
ESGO eAcademy, Isabelle Ray-Coquard, 403747
Should All HRD/BRCA WT Patients Be Treated With PARP+ Antiangiogenic Agents? PRO Opinion
ESGO eAcademy, Antonio Gonzalez-Martin, 403746
Discussant
ESGO eAcademy, Viola Heinzelmann-Schwarz, 403740
A Step-By Step Site-Relapse Modified Lateral Extended Endopelvic Resection (LEER)
ESGO eAcademy, Marta de la Cruz, 403745
Antibody Drug Conjugate Adverse Events and Mitigation Strategies
ESGO eAcademy, Toon Van Gorp, 403733
HPV Prevention Policy Atlas Europe - Tracking Government Policies In Europe On Access To HPV Vaccination, Screening And Information
ESGO eAcademy, Marina Davidashvili, 403739
Robotic Retroperitoneal Debulking - Case Report With Tips And Tricks For A Safe Procedure
ESGO eAcademy, Fernando De Souza Nobrega, 403744
Cervical Cancer: Antibody Drug Conjugate Development, Efficacy, and Access for Patients Globally
ESGO eAcademy, Nicole Concin, 403732
Pembrolizumab + Chemotherapy for First-Line Treatment of Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results and Bevacizumab Subgroup Analysis of KEYNOTE-826
ESGO eAcademy, Bradley J. Monk, 403738
Abdominal Radical Trachelectomy: A Video Presentation
ESGO eAcademy, ali gokce, 403743
Antibody Drug Conjuate Development in Endometrial Cancer: HER2 Targeting is on the Horizon, What Other Agents Are Poised to Impact Patient Care?
ESGO eAcademy, Kathleen Moore, 403731
Lower-Limb Lymphedema After Sentinel Lymph Node Biopsy In Cervical Cancer Patients: Final Results Of The SENTIX Prospective International Study (CEEGOG CX-01/ ENGOT-Cx2)
ESGO eAcademy, Christhardt Koehler, 403736
First Birth After Uterine Transposition For Cervical Cancer - Surgical Technique And Case Report
ESGO eAcademy, Fernando De Souza Nobrega, 403742
Discussant
ESGO eAcademy, Antonia Carla Testa, 403735
Laparoscopic Assisted Vaginal Radical Trachelectomy With Prophylactic Cerclage: A Safe Fertility Sparing Treatment For Early-Stage Cervical Cancer
ESGO eAcademy, Pavone Matteo, 403741
Magnetic Resonance Imaging Or Expert Ultrasound In Preoperative Local Staging Of Patients With Early-Stage Cervical Cancer: Final Results Of The SENTIX Prospective, Single-Arm, International Trial (CEEGOG CX-01; ENGOT-CX2)
ESGO eAcademy, Kocian Roman, 403734
Atatürk, Republic of Türkiye and Women Rights
ESGO eAcademy, Victor Gomel, 403645
40th Anniversary Celebration with Past Presidents of ESGO
ESGO eAcademy, Nicole Concin, 403729
Laudation Speech
ESGO eAcademy, Andreas du Bois, 403728
Audience Q&A
ESGO eAcademy, Domenica Lorusso, 403721
New Combinations and Novel Targets: Ongoing Research in Endometrial Cancer
ESGO eAcademy, Bradley J. Monk, 403720
Safety Considerations and Quality of Life from Anti-PD-1 Combination Trials
ESGO eAcademy, Nicole Concin, 403719
Recent Data from Anti-PD-1 Combination Trials in Primary Advanced or Recurrent Endometrial Cancer
ESGO eAcademy, Domenica Lorusso, 403718
A Restrictive Stoma Policy After Colorectal Anastomosis? Yes We Can!
ESGO eAcademy, Victor Lago, 403717
Real-World Utilisation And Clinical Outcomes Of Patients With BRCA-Mutated Advanced Ovarian Cancer Treated With Olaparib In The First-Line Maintenance Setting: 2-Year Clinical Outcomes Of The Pan-European OVAL-1 Study
ESGO eAcademy, Domenica Lorusso, 403716
Human Papilloma Virus 16/18 Genotyping With Dual Staining For The Detection Of High Grade Cervical Intraepithelial Neoplasia In Women With Low Grade Cytology.
ESGO eAcademy, Gauri Gandhi, 403715
Application Of PAX1 And JAM3 Gene Methylation Detection As A Triage Tool For Cervical Cancer Screening In Women: Analysis Of A Single-Center Prospective Study In China
ESGO eAcademy, Huafeng Shou, 403714
Fertility Preservation in Stage IB2 Cervical Cancer: Radical Trachelectomy by Abdominal Approach
ESGO eAcademy, Nadeem R. Abu-Rustum, 403706
HPV Status As A Triage Mechanism In The Follow-Up Of Patients With Adenocarcinoma In Situ And Microinvasive Adenocarcinoma Of The Uterine Cervix - A Retrospective Study.
ESGO eAcademy, Lukas Dostalek, 403712

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings